
April 15 (Reuters) - Spruce Biosciences Inc SPRB.O:
SPRUCE BIOSCIENCES ANNOUNCES NEW CORPORATE STRATEGY AND ACQUISITION OF TRALESINIDASE ALFA FOR THE TREATMENT OF SANFILIPPO SYNDROME TYPE B (MPS IIIB)
SPRUCE BIOSCIENCES INC - BLA SUBMISSION TO FDA FOR TA-ERT ANTICIPATED IN 1H 2026
SPRUCE BIOSCIENCES INC: EXPECTS ITS CASH RUNWAY TO FUND ITS CURRENT OPERATING PLAN THROUGH END OF 2025